GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Sep 16, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on September 16, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- September 2025 (date) — Reporting period
- 20250916 (date) — Filing date
FAQ
What specific number of GSK plc ordinary shares were purchased?
The filing states that a 'following number' of shares were purchased but does not specify the exact quantity.
What was the total dollar amount of the share repurchases?
The filing does not disclose the total dollar amount spent on the share repurchases.
When did these share transactions take place?
The filing is for the month of September 2025, and the transactions are announced on September 16, 2025.
Who acted as GSK's stockbroker for these transactions?
Merrill Lynch International acted as GSK's corporate stockbroker.
Is GSK plc filing an annual report on Form 20-F?
Yes, GSK plc indicated with an 'X' that it files annual reports under cover of Form 20-F.
Filing Stats: 2,920 words · 12 min read · ~10 pages · Grade level 3.4 · Accepted 2025-09-16 09:24:26
Filing Documents
- a4129z.htm (6-K) — 9219KB
- 0001654954-25-010794.txt ( ) — 9220KB
From the Filing
IN OWN SHARES a4129z   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   15 September 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   253,331   Lowest price paid per share (GBp):   1,476.00p   Highest price paid per share (GBp):   1,505.50p   Volume-weighted average price paid per share (GBp):   1,482.92p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 28,894,340 ordinary shares.   Following the above purchase, the Company will hold 247,028,723 ordinary shares in treasury and have 4,068,374,245 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is 4,068,374,245. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.07 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:        GSK plc (ISIN: GB00BN7SWP63) Date of purchases:       15 September 2025   Investment firm:          Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   253,331   1,505.50p   1,476.00p   1,482.92p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   12   1,503.50    XLON   15-Sep-2025   08:00:26   0XL0610000000000346F03   3   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0611000000000346FCL   4   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0614000000000346FB2   4   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0640000000000346F9Q   12   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0614000000000346FB1   12   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0614000000000346FB3   12   1,505.50    XLON   15-Sep-2025   08:00:28   0XL0617000000000346FBD   12   1,505.50    XLON   15-Sep-2025